AbbVie (ABBV.US) has reached a settlement with a generic drug company over its core immunotherapy drug, Rinvoq.

According to the Zhtng Cijng app, AbbVie (ABBV.US) announced on Thursday that they have reached a settlement with all the generic drug companies involved in the lawsuit, resolving the litigation related to the "generic drug companies plan to launch a generic version of Rinvoq". Rinvoq is a core drug in AbbVie's immunotherapy product line.